Intraperitoneal (i.p.) injection of murine recombinant IL-1β'/> Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis
首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis
【2h】

Investigation of the functional role played by the chemokine monocyte chemoattractant protein-1 in interleukin-1-induced murine peritonitis

机译:趋化因子单核细胞趋化蛋白-1在白介素1诱导的鼠腹膜炎中的功能作用研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">Intraperitoneal (i.p.) injection of murine recombinant IL-1β (mrIL-1β) produced a dose-dependent (0.5–50 ng) and time-related (0.5–2 h) secretion of murine monocyte chemoattractant protein-1 (mMCP-1; 3–4 ng per cavity) in the lavage fluids. MCP-1 mRNA could also be detected in the cell pellets by reverse transcriptase-polymerase chain reaction (RT-PCR).MCP-1 levels were reduced by more than 90% by co-administration of IL-1 receptor antagonist (10 μg) (n=6, P<0.05). In contrast, an IL-1 mutant with low affinity for IL-1 receptor type I, termed yIL-1βΔ4 (50 ng), produced only a modest release of the chemokine. Treatment of mice with dexamethasone (DEX) (∼1 mg kg−1 s.c.) reduced mrIL-1β-induced mMCP-1 gene expression (apparent total inhibition) and protein release in the lavage fluids (∼40% reduction; n=10; P<0.05). Drastic reductions in the numbers of residential macrophages or mast cells did not modify the levels of mMCP-1 recovered in the lavage fluids.Injection of mrIL-1β produced neutrophil accumulation into the peritoneal cavities (maximal at 4 h with 1.42±0.15×106 cells per mouse). Co-injection of a specific polyclonal antibody against mMCP-1 reduced this process by more than 50% (n=6; P<0.05). In conclusion, we studied the mechanisms leading to the specific release of the CC chemokine mMCP-1 after in vivo administration of mrIL-1β.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> 腹膜内(ip)注射鼠重组IL-1β(mrIL-1β)可产生鼠单核细胞趋化蛋白-1(mMCP-1)的剂量依赖性(0.5-50μng)和时间相关性(0.5-2h)。灌洗液中每个腔3–4 ng)。逆转录-聚合酶链反应(RT-PCR)还可以在细胞沉淀中检测到MCP-1 mRNA。 lili的共同给药可使MCP-1水平降低90%以上。 1种受体拮抗剂(10μg)(n = 6,P <0.05)。相反,对于I型受体IL-1受体的亲和力低的IL-1突变体,称为yIL-1βΔ4(50μng),仅产生适度的趋化因子释放。用地塞米松(DEX)(〜1μmgkg -1 sc)处理小鼠可降低mrIL-1β诱导的mMCP-1基因表达(表观总抑制)和灌洗液中的蛋白质释放(约40)减少%; n = 10; P <0.05)。驻留巨噬细胞或肥大细胞数量的急剧减少并没有改变灌洗液中回收的mMCP-1的水平。 注射mrIL-1β会导致中性粒细胞积累进入腹膜腔(最大4maxh)每只小鼠1.42±0.15×10 6 个细胞)。共注射针对mMCP-1的特异性多克隆抗体可将这一过程减少50%以上(n = 6; P <0.05)。总之,我们研究了体内施用mrIL-1β后导致CC趋化因子mMCP-1特异性释放的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号